NCT01111903

Who might be able to join this trial:

• You are over 18 years old.
• You have been diagnosed with epithelial ovarian cancer, fallopian tube cancer, or a related type called extra-ovarian papillary serous tumor, confirmed by a tissue sample (biopsy).
• Your cancer has come back or gotten worse more than 6 months after receiving a treatment plan that included a platinum-based drug (such as carboplatin or cisplatin).
• You have previously been treated with a taxane-based drug (such as paclitaxel or docetaxel).
• Your cancer progression has been detected through rising CA-125 blood marker levels and/or visible tumors on scans.
• Your blood counts, kidney function, and liver function are within acceptable levels (the trial team will check this with blood tests).
• You are generally well enough to carry out normal daily activities, with little or no limitation (confirmed by a doctor's assessment).
• You are expected to live for at least 16 weeks.
• For one part of the trial (Stage B): your heart pumping function is within a certain range (confirm with trial site).
• For one part of the trial (Stage B): if you were already in Stage A of this trial on a drug called lenalidomide and your disease got worse but you did not have serious side effects, you may be eligible after stopping lenalidomide for 7 days.
• You are willing and able to give written informed consent after being fully informed about the trial.

Who may not be able to join:

• Your ovarian tumor is classified as "borderline" (low malignant potential) rather than fully cancerous.
• Your tumor is a non-epithelial type or a mixed type (such as mixed Mullerian tumor).
• You have been diagnosed with another cancer in the last 5 years that required more than surgery alone to treat (exceptions may apply for certain minor skin cancers or cervical in-situ carcinoma — confirm with trial site).
• You have previously had radiotherapy.
• You have brain metastases (cancer that has spread to the brain) that are causing symptoms.
• You have a history of seizures, a central nervous system disorder, or existing nerve-related symptoms (such as numbness or weakness) above a mild level.
• You have a history of significant heart failure, a heart attack in the last 6 months, or certain types of heart rhythm problems.
• You have had a blood clot or have been on blood-thinning treatment within the last 6 months.
• You have had internal bleeding or a stomach/intestinal ulcer within the last 6 months.
• You have a bowel blockage or partial blockage.
• You have a serious active infection.
• You have another serious medical condition (unrelated to cancer) that could put you at significant risk or prevent you from fully participating in the study.
• You are a woman who could become pregnant and is not using adequate contraception, or you are currently pregnant or breastfeeding.
• You have a known allergy to carboplatin, pegylated liposomal doxorubicin, lenalidomide, or any of their ingredients.
• You have previously had a severe skin reaction (a blistering or peeling rash) while taking thalidomide or a similar drug.
• You have previously been treated with lenalidomide.
• You are known to be HIV-positive, have AIDS-related illness, or have active Hepatitis A, B, or C.
• You are currently receiving other chemotherapy, hormone therapy (except hormone replacement therapy or steroid anti-sickness medications), or radiotherapy at the same time as this trial treatment.
• You have dementia or a significantly impaired mental state that would prevent you from understanding and consenting to the trial.

Important: Always verify eligibility with the trial site directly before applying.